LIPOPROTEIN CHANGES AND INCREASED AFFINITY OF LDL FOR THEIR RECEPTORS AFTER ACIPIMOX TREATMENT IN HYPERTRIGLYCERIDEMIA

被引:24
作者
FRANCESCHINI, G
BERNINI, F
MICHELAGNOLI, S
BELLOSTA, S
VACCARINO, V
FUMAGALLI, R
SIRTORI, CR
机构
[1] Center E. Grossi Paoletti, Institute of Pharmacological Sciences, University of Milan, Milan
关键词
Acipimox; Hypertriglyceridemia; LDL receptor; Low density lipoproteins; Nicotinic acid;
D O I
10.1016/0021-9150(90)90057-P
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Modifications in plasma low and high density lipoprotein (LDL and HDL) subfraction distribution, as well as the regulation of cellular LDL metabolism by hypertriglyceridemic LDL were tested before and after treatment with acipimox, a nicotinic acid derivative, in 11 type IV hyperlipidemic patients. Large, less dense LDL particles were found in plasma after acipimox treatment, reflecting compositional changes, characterized by a 25.4% increase in cholesteryl ester content and by a 46.2% reduction of triglycerides in LDL. HDL subfractions were only slightly modified, with an increase of dense, cholesteryl ester-enriched and triglyceride poor HDL3 particles. The LDL (B,E) receptor activity in humans skin fibroblasts of LDL isolated before and after treatment was also evaluated. Hypertriglyceridemic LDL proved rather inefficient in regulating receptor activity with a close to 30% reduction vs. normal LDL in the capacity to inhibit receptor-mediated uptake and degradation of 125I-LDL. Such abnormality was fully corrected after acipimox. The reported findings indicate that acipimox treatment in type IV patients, in spite of a relatively modest plasma triglyceride reduction, can markedly modify LDL distribution and composition, normalizing the defective interaction of hypertriglyceridemic LDL with the LDL (B,E) receptor. © 1990.
引用
收藏
页码:41 / 49
页数:9
相关论文
共 29 条
[1]  
AVIRAM M, 1988, 8TH INT S ATH ROM
[2]   METABOLISM OF VERY LOW-DENSITY LIPOPROTEIN PROTEINS .1. PRELIMINARY IN-VITRO AND IN-VIVO OBSERVATIONS [J].
BILHEIMER, DW ;
LEVY, RI ;
EISENBERG, S .
BIOCHIMICA ET BIOPHYSICA ACTA, 1972, 260 (02) :212-+
[3]  
BOBERG J, 1971, METABOLIC EFFECTS NI, P466
[4]   REGULATION OF ACTIVITY OF LOW-DENSITY LIPOPROTEIN RECEPTOR IN HUMAN FIBROBLASTS [J].
BROWN, MS ;
GOLDSTEIN, JL .
CELL, 1975, 6 (03) :307-316
[5]  
BUCOLO G, 1973, CLIN CHEM, V19, P476
[6]   15 YEAR MORTALITY IN CORONARY DRUG PROJECT PATIENTS - LONG-TERM BENEFIT WITH NIACIN [J].
CANNER, PL ;
BERGE, KG ;
WENGER, NK ;
STAMLER, J ;
FRIEDMAN, L ;
PRINEAS, RJ ;
FRIEDEWALD, W .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1986, 8 (06) :1245-1255
[7]  
CARLSON LA, 1974, ATHEROSCLEROSIS, V3, P768
[8]   PLASMA-LIPID LOWERING ACTIVITY OF ACIPIMOX IN PATIENTS WITH TYPE-II AND TYPE-IV HYPERLIPOPROTEINEMIA - RESULTS OF A MULTICENTER TRIAL [J].
CREPALDI, G ;
AVOGARO, P ;
DESCOVICH, GC ;
DIPERRI, T ;
POSTIGLIONE, A ;
SIRTORI, CR ;
STRANO, A ;
VENTURA, S ;
MUSATTI, L .
ATHEROSCLEROSIS, 1988, 70 (1-2) :115-121
[9]   ABNORMALITIES IN VERY LOW, LOW, AND HIGH-DENSITY LIPOPROTEINS IN HYPERTRIGLYCERIDEMIA - REVERSAL TOWARD NORMAL WITH BEZAFIBRATE TREATMENT [J].
EISENBERG, S ;
GAVISH, D ;
OSCHRY, Y ;
FAINARU, M ;
DECKELBAUM, RJ .
JOURNAL OF CLINICAL INVESTIGATION, 1984, 74 (02) :470-482
[10]   CHOLESTEROL NET TRANSPORT, ESTERIFICATION, AND TRANSFER IN HUMAN HYPERLIPIDEMIC PLASMA [J].
FIELDING, PE ;
FIELDING, CJ ;
HAVEL, RJ ;
KANE, JP ;
TUN, P .
JOURNAL OF CLINICAL INVESTIGATION, 1983, 71 (03) :449-460